Gaudium IVF and Women Health sets September results review November 12

Gaudium IVF and Women Health Limited is scheduled to consider unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, at its board meeting on November 12, 2026. The board will also take on record the auditor's limited review report, setting the date for Gaudium IVF's next financial disclosure.

What will Gaudium IVF's board consider on November 12?

Gaudium IVF's board is scheduled to consider and approve unaudited financial results for the quarter and half-year ended September 30, 2026. The results will be prepared on both a standalone and consolidated basis, as stated in the company's November 6 filing with BSE.

The board is also expected to take on record the auditor's limited review report for the reported period. A limited review is part of the quarterly financial reporting process and accompanies the unaudited results disclosed by listed companies. The filing does not provide revenue, profit, margin, patient-volume, or other operating figures ahead of the board meeting.

The announcement establishes a formal results date rather than reporting the September-quarter numbers themselves. Investors will need to wait for the board's approved results and related exchange disclosure for the company's reported financial performance during the quarter and first half of the financial year.

Which disclosures accompany the September-quarter results process?

The company has stated that its trading window has remained closed from October 1, 2026 until 48 hours after the results are announced. Gaudium IVF said the closure and related disclosures will be made available on its website.

The trading-window restriction is linked to the forthcoming financial results, which may constitute unpublished price-sensitive information before public release. The company has not indicated any change to its operations, capital structure, or business strategy in the board-meeting intimation.

Gaudium IVF has also scheduled an earnings conference call to discuss the financial results with management. The disclosed participants include the Chairperson and Managing Director and the Chief Financial Officer. The supplied announcement does not specify the call timing or provide an earnings presentation.

What is the background to Gaudium IVF's latest filing?

Gaudium IVF's latest results-related filing follows its annual corporate reporting and shareholder-meeting activity during 2026. The company filed its annual report for the financial year 2025-26 on September 3, 2026, and held its 11th Annual General Meeting through video conferencing and other audio-visual means on September 28, 2026.

At the AGM, shareholders approved all five proposed resolutions with the requisite majority, according to the supplied information. These included adoption of audited financial statements, director-related matters, remuneration-related resolutions, and the appointment of Suresh Nainwal & Company as secretarial auditors for five years. No invalid votes were reported across the resolutions.

Earlier, Gaudium IVF had informed BSE that its board would meet on May 28, 2026 to consider audited standalone and consolidated financial statements and results for the quarter and year ended March 31, 2026. The September-period review is therefore the next disclosed board process for financial reporting after the annual-results cycle.

How does the scheduled results review matter to investors?

The November 12 meeting matters because it will provide the first disclosed financial update for Gaudium IVF covering the quarter and half-year ended September 30, 2026. The standalone results will show the company's own reported performance, while consolidated results will present financial information for the group as reported by the company.

At present, the provided filings contain no September-quarter revenue, net profit, earnings per share, expense, cash-flow, or balance-sheet figures. As a result, no quantified assessment of the company's financial performance or share-market reaction can be made from the board-meeting notice alone.

For investors, the key disclosures will be the approved financial statements, the limited review report, and any management comments issued during or after the earnings call. The 48-hour post-results trading-window period also marks the time frame identified by the company for handling the information before normal insider-trading restrictions are lifted.

The filing does not announce an acquisition, fund raise, dividend, expansion plan, or operational disruption. Its immediate relevance is the scheduled release of regulated financial information, which will give shareholders and market participants a current basis to assess the company's reported performance.

Conclusion

Gaudium IVF has fixed November 12, 2026 for board consideration of unaudited standalone and consolidated results for the September 30 quarter and half-year, along with the auditor's limited review report. The announcement confirms the reporting timetable but does not disclose any financial or operating performance figures in advance.

The next item to watch is the board-approved results release and the management discussion on the scheduled earnings conference call. Those disclosures should provide the reported figures and management context that are absent from the current board-meeting intimation.